Legal & General Group
FTH

Legal & General Group’s Faeth Therapeutics FTH Stock Holding History

Legal & General Group’s Portfolio FTH Stock Details FTH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-84
Closed -$4K – 3483
2022
Q2 		$4K Hold
84
– – ﹤0.01% 3460
2022
Q1 		$4K Hold
84
– – ﹤0.01% 3521
2021
Q4 		$10K Hold
84
– – ﹤0.01% 3467
2021
Q3 		$18K Buy
84
+54
+180% +$9.83K ﹤0.01% 3311
2021
Q2 		$6K Sell
30
-6
-17% -$1.48K ﹤0.01% 3460
2021
Q1 		$10K Buy
+36
New +$12K ﹤0.01% 3384

Other funds holding FTH

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
NM
Newtyn Management New York $936M AUM 27.23% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return
DFO
Duquesne Family Office New York $3.38B AUM 61.92% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
E
Ergoteles New York $68.2M AUM 36.16% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Legal & General Group's FTH Position: Q3 2022 in Review

Legal & General Group sold out of Faeth Therapeutics (FTH) in Q3 2022, closing a stake of 84 shares — an estimated $4K sold.

Legal & General Group first reported a position in FTH in Q1 2021 and held it in 6 quarters. The position peaked at $18K in Q3 2021. 30 funds tracked by Wall St. Rank hold FTH as of Q3 2022.

  • Legal & General Group reported no remaining Faeth Therapeutics position as of Q3 2022 after selling out during the quarter.
  • Legal & General Group sold 84 Faeth Therapeutics shares in Q3 2022, an estimated $4K.
  • Legal & General Group first reported a position in Faeth Therapeutics in Q1 2021 and held it in 6 quarters.
  • Legal & General Group's Faeth Therapeutics position peaked at $18K in Q3 2021.
  • 30 funds tracked by Wall St. Rank held Faeth Therapeutics as of Q3 2022.

Based on Legal & General Group's 13F filing for Q3 2022, filed 14 Nov 2022.